IRIX IRIDEX Corp Forecast, Technical & Fundamental Analysis
IRIDEX Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases... Show more
IRIX is expected to report earnings to fall 71.43% to -1 cents per share on November 17
Q3'26
Est.
$-0.02
Q2'26
Missed
by $0.05
Q1'26
Beat
by $0.02
Q4'25
Beat
by $0.01
Q3'25
Missed
by $0.03
The last earnings report on August 18 showed earnings per share of -7 cents, missing the estimate of -1 cents. With 97.76K shares outstanding, the current market capitalization sits at 13.16M.
A.I. Advisor
published General Information
General Information
a manufacturer of light-based medical systems and delivery devices
A.I.dvisor tells us that IRIX and NTRA have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IRIX and NTRA's prices will move in lockstep.
IRIX sees MACD Histogram crosses below signal line
IRIX saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on August 21, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 42 instances where the indicator turned negative. In of the 42 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on August 19, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IRIX as a result. In of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IRIX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
IRIX broke above its upper Bollinger Band on August 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for IRIX entered a downward trend on August 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IRIX's RSI Indicator exited the oversold zone, of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IRIX advanced for three days, in of 210 cases, the price rose further within the following month. The odds of a continued upward trend are .
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. IRIX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: IRIX's P/B Ratio (270.270) is very high in comparison to the industry average of (11.035). P/E Ratio (0.000) is within average values for comparable stocks, (70.949). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.006). IRIX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.017). P/S Ratio (0.253) is also within normal values, averaging (34.463).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IRIX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
